Current Report Filing (8-k)
December 11 2018 - 5:10PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported):
December 7, 2018
ONCOSEC
MEDICAL INCORPORATED
(Exact
Name of Registrant as Specified in Charter)
Nevada
|
|
000-54318
|
|
98-0573252
|
(State
or Other Jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
Incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
3565
General Atomics Court, Suite 100
San Diego, California 92121
24
North Main Street
Pennington,
NJ 08534-2218
(Address
of Principal Executive Offices)
(855)
662-6732
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act.
|
|
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act.
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2b under the Exchange Act.
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act.
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
8.01 Other Events.
On
December 7, 2018 OncoSec Medical Incorporated (the “Company”) completed the second closing of 4,666,667 shares
of its common stock, par value $0.0001 per share, (the “Common Stock”) at a price of $1.50 per share pursuant
to the Company’s previously announced registered direct offering with Alpha Holdings, Inc. (“Alpha”). The Company
received total proceeds from the offering, before expenses, of $8 million in cash from the first closing and $7 million in cash
from the second closing. In connection with the offering, on August 31, 2018 the Company entered into a stock purchase agreement
(the “Purchase Agreement”) with Alpha. There were no underwriting or placement agent fees associated with the offering.
The
Company had previously registered the shares of Common Stock sold in connection with the registered direct offering with the Securities
and Exchange Commission (the “SEC”) pursuant to a Registration Statement on Form S-3, as amended (File No. 333-213036)
(the “Registration Statement”) filed on August 9, 2016, and declared effective by the SEC August 26, 2016, covering
shares of the Company’s Common Stock. The Company is filing this current report on Form 8-K in order to cause certain information
contained herein and in the exhibits hereto to be incorporated into the Registration Statement by reference.
The
summary of the Purchase Agreement set forth above does not purport to be complete and is subject to and qualified in its entirety
by reference to the text of such agreement.
Item
9.01 Financial Statements and Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
ONCOSEC MEDICAL INCORPORATED
|
|
(Registrant)
|
|
|
|
Date:
December 11, 2018
|
By:
|
/s/
Daniel J. O’Connor
|
|
Name:
|
Daniel
J. O’Connor
|
|
Title:
|
Chief
Executive Officer and President
|
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Mar 2024 to Apr 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Apr 2023 to Apr 2024